NVCR NovoCure
NovoCure earnings company data as of 8:01 PM ET 10/22
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 29 Oct | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by NVCR's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $596K sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Mukund Paravasthu COOSale$596K 43,246 shares at $13.77 37% of stakeTraded Mar 5 Filed Mar 5
Also filed in the last 12 months, not counted as buying or selling: 24 stock grants, 24 sales to cover taxes, 10 share withholdings for taxes, and 1 option exercise.
SEC filings
Recent issuer filings from EDGAR, 19 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 5.02,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| DEFA14A | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K/A | 5.02,9.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 5.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.